Small studies have found that B-cell depletion with rituximab may be beneficial in refractory antineutrophil cytoplasmic antibody-associated (ANCA-associated) vasculitis, due to the presence of ...

Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study Clinical trials frequently include multiple end points that mature at ...

Following implementation of low-dose rituximab as standard of care for muscle-specific kinase–positive myasthenia gravis (MuSK-MG), a hospital evaluated the treatment’s efficacy over a 2-year period.

Because MS patients who take rituximab have more relapses than those who take ocrelizumab, these two therapies may not be interchangeable in clinical practice. Ocrelizumab was the first licensed ...

Belimumab and rituximab demonstrated promise as potential treatments for both refractory and severe childhood systemic lupus erythematosus. Belimumab and rituximab demonstrated promise as potential ...

Columvi plus chemo had enhanced survival outcomes vs Rituxan plus chemo in patients with relapsed/refractory diffuse large B-cell lymphoma. Among patients with relapsed/refractory diffuse large B-cell ...

Reporting on the real-world utilization of reference rituximab and its biosimilars can help show prescribing habits and reveal cost-saving opportunities. Objectives: Limited data exist on the adoption ...